Thus, in addition to EGFR-FOXO6-SOX2 feedback loop, the expression of FOXO6 can also be regulated by FOXO6-eRNA, which provided novel implications for the targeted therapy of FOXO6-related erlotinib resistance in lung cancer patients. Here, FOXO6 is linked to lung carcinoma.